What challenges do entrepreneurs face in order to turn a research concept into a successful company with viable treatments?

Find out on April 19th at this month's MIT/Stanford Venture Lab, where Jeffrey Ostrove, CEO of Ceregene, discusses how they overcame scientific challenges, negotiated licensing deals, and obtained $32 million in venture financing, in their quest to develop the first gene therapy treatment for neurological disorders.

Panelist adding their perspectives to the discussion include: David Mack, Director of early life science investments at Alta Partners, David Summa, President and CEO of Acumen Pharmaceuticals, Thorsten Melcher, Vice President of Discovery at Saegis Pharmaceuticals, and Frank Eeckman, Managing Editor of Centient Biotech Investor will also be sharing their thoughts on critical pitfalls and opportunities in neuropharmaceutical discovery and development.

Please join me, as I moderate this panel of experts through a discussion that will help entrepreneurs, researchers, venture investors and the general public learn how they too can tap into the booming neurotechnology market.

Event Details:
Date: Tuesday, April 19, 2005
Time: 6:00 PM - Reception, Arbuckle Lounge, Stanford Business School
7:00 PM - Presentation & Discussion, Bishop Auditorium, SBS
Directions: (Click here)
Registration: (click here)